Jennifer E. Miller, PhD, is an Assistant Professor at the NYU School of Medicine and President of the nonprofit, Bioethics International. She is also the Creator of the Good Pharma Scorecard, an index that ranks all new drugs and large pharmaceutical companies on their ethics and public health performance to help recognize good practices in companies, improve trustworthiness, and incentivize change where needed. Prior to joining NYU, Dr. Miller was based at Harvard University.
Dr. Miller currently serves on NYU’s Pharmacy and Therapeutics Committee and Stem Cell Research Oversight IRB, as well as
the J&J-NYU Compassionate-Use Advisory Committee (monitor). Previously, she served on the Center for Disease Control and Prevention’s (CDC) Task Force for Pediatric Emergency Mass Critical Care, the American Medical Association’s (AMA) Advanced Disaster Life Support Education Consortium, as a consultant to the United Nations Economic and Social Council, and on the PCORI-NIH Collaboratory.
A prolific writer, Dr. Miller has authored over 35 articles in publications including Nature Medicine and Health Affairs. She was a Fox News pundit from 2009 to 2012 and remains a news commentator, frequently featured on CBS news, Wall Street Journal, Washington Post, Bloomberg News, Forbes, and NPR.
Dr. Miller’s current work explores the ethics and governance of new drugs that are researched, developed, marketed, priced, and made accessible to patients globally. She also specializes in the ethics of data sharing.
00:00 EP148: Jennifer E. Miller, PhD, Bioethics International and Creator of the Good Pharma Scorecard.
01:00 The Good Pharma Scorecard rankings for 2017.
01:40 Two 100% transparent pharma companies.
02:20 Two stats that prove that Pharma companies are improving.
03:00 Industry improvements on patient trials.
03:25 Ninety-six percent of all patient trials are available to the public.
03:45 Where there wasn’t a significant improvement in disclosure in pharma.
Related Episodes
Encore! EP397: The Minefield That Is a PBM Contract and Also Some Advice for EBCs Who Are Taking Money Under the Table, With Paul Holmes
Today is an encore because I am going on vacation next week. It always feels a little bit like a time warp because by the time this show will air, I will be back from vacation. This show with Paul Holmes was one of the most popular episodes of 2023 and definitely is just as relevant now. A lot of t...
EP439: Fixing the Generic Drug Pricing Problem, Where Patients Pay More When They Use Their Insurance, With Luke Slindee, PharmD
In the Ge Bai show ( EP420 ), one solve was offered for helping patients pay the lowest possible price for generic drugs. In this healthcare podcast, Luke Slindee, PharmD, offers another solve. That’s where this conversation is going, but now let’s start from the beginning. For a full transcript of...
EP435: Optimized Pharmacy Benefits Are Required if You Want to Do or Buy Value-Based Care, With Dan Mendelson
This conversation I am having with Dan Mendelson, my guest today, all started with a post that he had written on LinkedIn considering how pharmacy benefits can or should be optimized within the broader context of value-based care. Total cost of care, value-based medical care, and pharmacy benefits—...